中国医疗保健国际交流促进会肝脏肿瘤学分会, 中国医学科学院北京协和医学院肿瘤医院消化道肿瘤多学科协作组, 中国医师协会肝癌专业委员会. 肝癌转化治疗中肝功能全程管理中国专家共识（2022版）[J]. 肝癌电子杂志, 2023, 10(1): 1-9.
| [1] CHEN W, ZHENG R, BAADE P D, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. [2] GLOBAL BURDEN OF DISEASE LIVER CANCER C, AKINYEMIJU T, ABERA S, et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015[J]. JAMA Oncol, 2017, 3(12): 1683-1691. [3] BRAY F, FERLAY J, SOERJOMATARAM I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. [4] ZHENG R, ZHANG S, ZENG H, et al.Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2(1): 1-9. [5] ZHOU M, WANG H, ZENG X, et al.Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204): 1145-1158. [6] ZENG H, CHEN W, ZHENG R, et al.Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5): e555-e567. [7] 中华人民共和国国家卫生健康委员会医政司.原发性肝癌诊疗指南(2022年版)[J/CD].肝癌电子杂志, 2022, 9(1): 1-22. [8] 中国抗癌协会肝癌专业委员会转化治疗协作组. 肝癌转化治疗中国专家共识(2021版)[J]. 中华消化外科杂志, 2021, 20(6): 600-616. [9] LAU W Y, LAI E C.Salvage surgery following downstaging of unresectable hepatocellular carcinoma--a strategy to increase resectability[J]. Ann Surg Oncol, 2007, 14(12): 3301-3309. [10] 董家鸿, 郑树森, 陈孝平, 等. 肝切除术前肝脏储备功能评估的专家共识(2011版)[J]. 中华消化外科杂志, 2011, 10(1): 20-25. [11] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)原发性肝癌诊疗指南2020[M]. 北京: 人民卫生出版社, 2020. [12] DE MARTEL C, GEORGES D, BRAY F, et al.Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis[J]. Lancet Glob Health, 2020, 8(2): e180-e190. [13] 中华预防医学会肝胆胰疾病预防与控制专业委员会,中国研究型医院学会肝病专业委员会,中华医学会肝病学分会,等.原发性肝癌的分层筛查与监测指南(2020版)[J/CD].肝癌电子杂志, 2021, 8(1): 1-15. [14] 中华医学会感染病学分会,中华医学会肝病学分会.慢性乙型肝炎防治指南(2019年版)[J/CD].中国医学前沿杂志(电子版), 2019, 11(12): 51-77. [15] LAO X M, LUO G, YE L T, et al.Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma[J]. Liver Int, 2013, 33(4): 595-604. [16] JANG J W, CHOI J Y, BAE S H, et al.Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma[J]. J Hepatol, 2004, 41(3): 427-435. [17] PENG J W, LIN G N, XIAO J J, et al.Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization therapy[J]. Asia Pac J Clin Oncol, 2012, 8(4): 356-361. [18] KIM J H, PARK J W, KIM T H, et al.Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2007, 69(3): 813-819. [19] MAIWALL R, KUMAR M.Prevention and Treatment of Recurrent Hepatitis B after Liver Transplantation[J]. J Clin Transl Hepatol, 2016, 4(1): 54-65. [20] LU W P, DONG J H.Hepatectomy for hepatocellular carcinoma in the era of liver transplantation[J]. World J Gastroenterol, 2014, 20(28): 9237-9244. [21] YIN J, LI N, HAN Y, et al.Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study[J]. J Clin Oncol, 2013, 31(29): 3647-3655. [22] HUANG G, LAU W Y, WANG Z G, et al.Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial[J]. Ann Surg, 2015, 261(1): 56-66. [23] HUANG G, LI P P, LAU W Y, et al.Antiviral Therapy Reduces Hepatocellular Carcinoma Recurrence in Patients With Low HBV-DNA Levels: A Randomized Controlled Trial[J]. Ann Surg, 2018, 268(6): 943-954. [24] GANNE-CARRIE N, NAHON P.Hepatocellular carcinoma in the setting of alcohol-related liver disease[J]. J Hepatol, 2019, 70(2): 284-293. [25] LARSSON S C, WOLK A.Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies[J]. Br J Cancer, 2007, 97(7): 1005-1008. [26] LENCIONI R, DE BAERE T, SOULEN M C, et al.Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data[J]. Hepatology, 2016, 64(1): 106-116. [27] 中华医学会外科学分会外科手术学学组,中国医疗保健国际交流促进会,加速康复外科学分会肝脏外科学组. 肝切除术后加速康复中国专家共识(2017版)[J]. 临床肝胆病杂志, 2017, 33(10): 1876-1882. [28] 中国研究型医院学会肝胆胰外科专业委员会. 精准肝切除术专家共识[J]. 中华消化外科杂志, 2017, 16(9): 883-893. [29] 海峡两岸医药卫生交流协会肿瘤防治专家委员会. 肝癌肝切除围手术期管理中国专家共识(2021年版)[J]. 中华肿瘤杂志, 2021, 43(4): 414-430. [30] ARENDS J, BARACOS V, BERTZ H, et al.ESPEN expert group recommendations for action against cancer-related malnutrition[J]. Clin Nutr, 2017, 36(5): 1187-1196. [31] PRESSOIR M, DESNE S, BERCHERY D, et al.Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres[J]. Br J Cancer, 2010, 102(6): 966-971. [32] MARTIN L, SENESSE P, GIOULBASANIS I, et al.Diagnostic criteria for the classification of cancer-associated weight loss[J]. J Clin Oncol, 2015, 33(1): 90-99. [33] 中华医学会肠外肠内营养学分会. 成人围手术期营养支持指南[J]. 中华外科杂志, 2016, 54(9): 641-657. [34] 赫捷, 陈万青, 沈洪兵, 等. 中国人群肝癌筛查指南(2022, 北京)[J]. 中华消化外科杂志, 2022, 21(8): 971-996. [35] 中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425. [36] CHOI G H, PARK J Y, HWANG H K, et al.Predictive factors for long-term survival in patients with clinically significant portal hypertension following resection of hepatocellular carcinoma[J]. Liver Int, 2011, 31(4): 485-493. [37] AN M, PARK J W, SHIN J A, et al.[The adverse effect of indirectly diagnosed portal hypertension on the complications and prognosis after hepatic resection of hepatocellular carcinoma][J]. Korean J Hepatol, 2006, 12(4): 553-561. [38] PANG Q, QU K, ZHANG J Y, et al.The Prognostic Value of Platelet Count in Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis[J]. Medicine (Baltimore), 2015, 94(37): e1431. [39] BENSON A B, D'ANGELICA M I, ABBOTT D E, et al. Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2021, 19(5): 541-565. [40] EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER. Electronic Address E E E, European Association for the Study of The L. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. [41] 罗文, 帖君. 肝癌合并门静脉高压的局部消融治疗[J]. 临床肝胆病杂志, 2021, 37(3): 515-521. [42] SCHRECKER C, WAIDMANN O, EL YOUZOURI H, et al.Low Platelet Count Predicts Reduced Survival in Potentially Resectable Hepatocellular Carcinoma[J]. Curr Oncol, 2022, 29(3): 1475-1487. [43] RAHBARI N N, GARDEN O J, PADBURY R, et al.Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS)[J]. Surgery, 2011, 149(5): 713-724. [44] ELSHAARAWY O, ALKHATIB A, ELHELBAWY M, et al.Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma[J]. World J Hepatol, 2019, 11(6): 542-552. [45] HUANG F, GAO J.Modified Child-Pugh grade vs albumin-bilirubin grade for predicting prognosis of hepatocellular carcinoma patients after hepatectomy[J]. World J Gastroenterol, 2020, 26(7): 749-758. [46] XIONG Y, MA Y, TIAN Y, et al.A Longitudinal Cohort Study Using a Modified Child-Pugh Score to Escalate Respiratory Support in COVID-19 Patients - Hubei Province, China, 2020[J]. China CDC Wkly, 2021, 3(20): 423-429. [47] 赵海涛, 毕新宇, 赵宏, 等. 肝细胞癌新辅助及转化治疗中国专家共识[J/CD]. 肝癌电子杂志, 2022, 9(1): 23-28. [48] KIM Y, STAHL C C, MAKRAMALLA A, et al.Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria[J]. Surgery, 2017, 162(6): 1250-1258. [49] LEWANDOWSKI R J, KULIK L M, RIAZ A, et al.A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization[J]. Am J Transplant, 2009, 9(8): 1920-1928. [50] LI B, QIU J, ZHENG Y, et al.Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma[J]. Ann Surg Open, 2021, 2(2): e057. [51] 陈荔, 滕皋军. TACE对原发性肝癌肝功能的损伤[J]. 东南大学学报(医学版), 2012, 31(5): 643-647. [52] HIRAOKA A, KUMADA T, KUDO M, et al.Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis[J]. Dig Dis, 2017, 35(6): 602-610. [53] AHMADZADEHFAR H, BIERSACK H J, EZZIDDIN S.Radioembolization of liver tumors with yttrium-90 microspheres[J]. Semin Nucl Med, 2010, 40(2): 105-121. [54] HOULE S, YIP T K, SHEPHERD F A, et al.Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres[J]. Radiology, 1989, 172(3): 857-860. [55] WEI X, JIANG Y, ZHANG X, et al.Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study[J]. J Clin Oncol, 2019, 37(24): 2141-2151. [56] SHANKER M D, LIU H Y, LEE Y Y, et al.Stereotactic radiotherapy for hepatocellular carcinoma: Expanding the multidisciplinary armamentarium[J]. J Gastroenterol Hepatol, 2021, 36(4): 873-884. [57] YOON S M, RYOO B Y, LEE S J, et al.Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial[J]. JAMA Oncol, 2018, 4(5): 661-669. [58] BYUN H K, KIM H J, IM Y R, et al.Dose escalation by intensity modulated radiotherapy in liver-directed concurrent chemoradiotherapy for locally advanced BCLC stage C hepatocellular carcinoma[J]. Radiother Oncol, 2019, 133: 1-8. [59] SON S H, JANG H S, JO I Y, et al.Significance of an increase in the Child-Pugh score after radiotherapy in patients with unresectable hepatocellular carcinoma[J]. Radiat Oncol, 2014, 9: 101. [60] JUN B G, KIM Y D, CHEON G J, et al.Clinical significance of radiation-induced liver disease after stereotactic body radiation therapy for hepatocellular carcinoma[J]. Korean J Intern Med, 2018, 33(6): 1093-1102. [61] CABIBBO G, AGHEMO A, LAI Q, et al.Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function[J]. Dig Liver Dis, 2022, 54(4): 452-460. [62] DE MATTIA E, CECCHIN E, GUARDASCIONE M, et al.Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma[J]. World J Gastroenterol, 2019, 25(29): 3870-3896. [63] HATANAKA T, KAKIZAKI S, NAGASHIMA T, et al.Liver Function Changes in Patients with Hepatocellular Carcinoma Treated with Lenvatinib: Predictive Factors of Progression to Child-Pugh Class B, the Formation of Ascites and the Candidates for the Post-Progression Treatment[J]. Cancers (Basel), 2020, 12(10): 2906. [64] EIGENTLER T K, HASSEL J C, BERKING C, et al.Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy[J]. Cancer Treat Rev, 2016, 45: 7-18. [65] PAN J, LIU Y, GUO X, et al.Risk factors for immune-mediated hepatotoxicity in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis[J]. Expert Opin Drug Saf, 2022, 21(10): 1275-1287. [66] ZHOU X, YAO Z, BAI H, et al.Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis[J]. Lancet Oncol, 2021, 22(9): 1265-1274. [67] MARTEL G, CIESLAK K P, HUANG R, et al.Comparison of techniques for volumetric analysis of the future liver remnant: implications for major hepatic resections[J]. HPB (Oxford), 2015, 17(12): 1051-1057. [68] SCHADDE E, ARDILES V, ROBLES-CAMPOS R, et al. Early survival and safety of ALPPS: first report of the International ALPPS Registry[J]. Ann Surg, 2014, 260(5): 829-836; discussion 836-828. [69] CHAN A, ZHANG W Y, CHOK K, et al.ALPPS Versus Portal Vein Embolization for Hepatitis-related Hepatocellular Carcinoma: A Changing Paradigm in Modulation of Future Liver Remnant Before Major Hepatectomy[J]. Ann Surg, 2021, 273(5): 957-965. [70] LI P P, HUANG G, JIA N Y, et al.Associating liver partition and portal vein ligation for staged hepatectomy versus sequential transarterial chemoembolization and portal vein embolization in staged hepatectomy for HBV-related hepatocellular carcinoma: a randomized comparative study[J]. Hepatobiliary Surg Nutr, 2022, 11(1): 38-51. [71] 徐珍, 赖小欢. 异甘草酸镁对经导管动脉栓塞化疗术后原发性肝癌患者肝功能和细胞免疫的影响[J]. 癌症进展, 2022, 20(15): 1546-1549. [72] 陈宏伟, 杨孙虎. 异甘草酸镁联合丁二磺酸腺苷蛋氨酸对原发性肝癌介入术后肝功能及预后的影响[J]. 医学临床研究, 2020, 37(2): 199-202. [73] 陆英, 王东盛, 王成纲, 等. 多烯磷脂酰胆碱治疗原发性肝癌TACE后肝损伤的研究[J]. 中国医药导报, 2011, 8(8): 77-78. [74] 宋燕, 陈金华, 易诗琼, 等. 还原型谷胱甘肽联合抗病毒肝动脉化疗栓塞治疗乙肝相关性肝癌的研究[J]. 解放军预防医学杂志, 2018, 36(7): 839-842. [75] 王永波, 何建新, 董立朋, 等. 射频消融术治疗原发性肝癌的临床疗效及对患者血清超氧化物歧化酶、谷胱甘肽及丙二醛水平的影响[J]. 中国临床医生杂志, 2017, 45(12): 58-61. [76] VINCENZI B, SANTINI D, FREZZA A M, et al.The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen[J]. Expert Opin Drug Saf, 2011, 10(3): 345-349. [77] 袁博, 张昕辉, 张灿灿, 等. 术前静滴思美泰对肝癌切除患者术后肝功能的影响及其机制探讨[J]. 山东医药, 2017, 57(34): 38-40. [78] 崔洪亮, 张阳德. 腺苷蛋氨酸(肠溶片)在TACE术后的护肝作用——前瞻性随机对照临床研究[J]. 中国现代医学杂志, 2012, 22(20): 75-78. [79] 武中林, 吴勇超, 杨超, 等. 原发性肝癌经导管肝动脉化疗栓塞术后应用不同保肝方案的效果比较研究[J]. 中国全科医学, 2017, 20(23): 2862-2867, 2874. [80] SANTAMBROGIO R, KLUGER M D, COSTA M, et al.Hepatic resection for hepatocellular carcinoma in patients with Child-Pugh's A cirrhosis: is clinical evidence of portal hypertension a contraindication?[J]. HPB (Oxford), 2013, 15(1): 78-84. [81] MARGONIS G A, AMINI N, BUETTNER S, et al.Impact of early postoperative platelet count on volumetric liver gain and perioperative outcomes after major liver resection[J]. Br J Surg, 2016, 103(7): 899-907. [82] WANG H Q, YANG J, YANG J Y, et al.Low immediate postoperative platelet count is associated with hepatic insufficiency after hepatectomy[J]. World J Gastroenterol, 2014, 20(33): 11871-11877. [83] ALKOZAI E M, NIJSTEN M W, DE JONG K P, et al. Immediate postoperative low platelet count is associated with delayed liver function recovery after partial liver resection[J]. Ann Surg, 2010, 251(2): 300-306. [84] PAUGAM-BURTZ C, JANNY S, DELEFOSSE D, et al.Prospective validation of the "fifty-fifty" criteria as an early and accurate predictor of death after liver resection in intensive care unit patients[J]. Ann Surg, 2009, 249(1): 124-128. [85] ROSS S W, SESHADRI R, WALTERS A L, et al.Mortality in hepatectomy: Model for End-Stage Liver Disease as a predictor of death using the National Surgical Quality Improvement Program database[J]. Surgery, 2016, 159(3): 777-792. [86] 北京医学会,肠外肠内营养学会专业委员会,《慢性肝病患者肠外肠内营养支持与膳食干预专家共识》专家委员会. 慢性肝病患者肠外肠内营养支持与膳食干预专家共识[J]. 中华肝胆外科杂志, 2017, 23(2): 73-81. [87] FUJITA M, TAKAHASHI A, HAYASHI M, et al.Skeletal muscle volume loss during transarterial chemoembolization predicts poor prognosis in patients with hepatocellular carcinoma[J]. Hepatol Res, 2019, 49(7): 778-786. [88] KOYA S, KAWAGUCHI T, HASHIDA R, et al.Effects of in-hospital exercise on sarcopenia in hepatoma patients who underwent transcatheter arterial chemoembolization[J]. J Gastroenterol Hepatol, 2019, 34(3): 580-588. [89] SCHMITZ K H, COURNEYA K S, MATTHEWS C, et al.American College of Sports Medicine roundtable on exercise guidelines for cancer survivors[J]. Med Sci Sports Exerc, 2010, 42(7): 1409-1426. [90] CAMPBELL K L, WINTERS-STONE K M, WISKEMANN J, et al. Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable[J]. Med Sci Sports Exerc, 2019, 51(11): 2375-2390. [91] CHEN Q, SHU C, LAURENCE A D, et al.Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial[J]. Gut, 2018, 67(11): 2006-2016. [92] ZHAI X F, LIU X L, SHEN F, et al.Traditional herbal medicine prevents postoperative recurrence of small hepatocellular carcinoma: A randomized controlled study[J]. Cancer, 2018, 124(10): 2161-2168. [93] QIN S K, LI Q, MING XU J, et al.Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival[J]. Cancer Sci, 2020, 111(11): 4218-4231. |
| No related articles found! |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
